II. Indications
- Peripheral T Cell Lymphoma (refractory or resistant)
III. Mechanism
- Antimetabolite, antineoplastic agent
- Belinostat inhibits tumor cell division, differentiation and Angiogenesis
- Histone Deacetylase Inhibitor (HDAC Inhibitor, hydroxamic acid-type)
- Histones are the spools around which DNA are wrapped, and which play a role in gene expression
- Cancers may be facilitated by abnormally expressed genes in specific histone regions
- HDAC Inhibitors block histone deacetylase
- Histone deacetylase is an enzyme that catalyzes removal of acetyl groups from core histones
- Results in hyperacetylation of histones, suppressing gene expression and cell differentiation
- Belinostat may also down regulate thymidylate synthase
- Sensitizes resistant tumor cells to other antineoplastics
IV. Medications
- Belinostat powder 500 mg for injection
V. Dosing
- Adult: 1000 mg/m2 IV daily on days 1 to 5 of a 21 day Chemotherapy cycle
VI. Adverse Effects
- Thrombocytopenia
- Neutropenia
- Hepatotoxicity
- Tumor Lysis Syndrome
VII. Safety
- Avoid in Pregnancy (any trimester)
- Fetal toxicity
- Use reliable Contraception
- Unknown safety in Lactation
- Monitoring